MedTrace Logo

Breast Stereotactic Radiotherapy to Primary Tumors in Metastatic Patients

NCT05229575 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-02-08

No results posted yet for this study

Summary

This is a dose escalation study involving stage IV breast cancer patients not progressing after 6 months of first line systemic treatment. Potential advantages of stereotactic body radiotherapy (SBRT) in treating breast primary tumor in metastatic breast cancer are:

* radio-biological advantage of a short highly effective treatment schedule
* possibility of preventing lesions to become symptomatic
* possibility of continuing systemic treatment without interruption

Conditions

  • Stage IV Breast Cancer

Interventions

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Undergo SBRT

Sponsors & Collaborators

  • Campus Bio-Medico University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-10
Primary Completion
2022-10-10
Completion
2023-04-10

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05229575 on ClinicalTrials.gov